Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 5, 2012, covering events that occurred on January 3, 2012. The filing pertains to personnel changes within Pacira Pharmaceuticals, Inc., specifically the appointment of a new General Manager for the San Diego facility and the retirement of a Senior Vice President.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and compensation arrangements rather than financial performance.
Material Changes
- Appointment: John Pratt was appointed as General Manager of the San Diego facility, effective January 3, 2012. He assumes duties previously held by Mark Walters, including oversight of commercial manufacturing, process development, feasibility research, and quality operations.
- Retirement: Mark Walters, Senior Vice President of Technical Operations, retired effective January 3, 2012.
- Compensation Structure: Mr. Pratt's employment agreement includes a base salary of $250,000, eligibility for an annual incentive bonus of up to 30% of base salary, and an option to purchase 30,000 shares of common stock (subject to board approval).
- Severance Terms: In the event of termination without cause or resignation for good reason, Mr. Pratt is eligible for nine months of salary continuation, nine months of accelerated option vesting, and 12 months of benefits continuation.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. The employment agreement is structured as "at-will," allowing either party to terminate employment at any time with or without cause.
Key Facts for Investor Verification
- Confirmation of the board's approval of the 30,000 share stock option grant to John Pratt.
- Verification of the transition plan for manufacturing operations following Mark Walters' immediate retirement.
- Assessment of the impact of the new leadership on the San Diego facility's commercial manufacturing timeline.